This ASX darling's price is now 'most attractive in 5 years': analyst

This old workhorse has served investors well for decades — but there's more legs in it yet, say two respected analysts.

| More on:
person waking up happy and stretching in bed

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An ASX-listed company that's been a long-time favourite among investors still has plenty of legs, according to one fund manager.

T Rowe Price Group Inc (NASDAQ: TROW) Australian equities head Randal Jenneke said Resmed CDI (ASX: RMD) stocks are now ripe for the picking.

"The valuation is now back to its most attractive level in 5 years," he told a T Rowe Price webinar last week.

"The sleep business is about to start to improve. As the US economy [improves] and there's a product cycle to come."

Resmed is a maker of medical devices that aid respiratory issues, especially in the area of sleep apnoea.

The Resmed share price had already climbed 7.18% over the week to Friday's market close. At the start of the month, it was 2% down for the year.

The business has given its shareholders a great deal of joy over the decades. The stock started at less than $1 at the turn of the millennia and has provided excellent annual returns, especially in the last dozen years.

An oldie but a goodie

Sage Capital portfolio manager Sean Fenton told The Motley Fool that Resmed's an old favourite.

"In various guises, we've owned [it] for well over a decade," he said in last week's Ask A Fund Manager.

"It had a few blips here and there from quarter to quarter but generally did very well and continued to grow and lead its segment."

Fenton agreed with Jenneke that there was more to come from the US company.

"There's still growth in its target market of sleep apnoea and improving sleep outcomes," he said.

"[The company has] invested more and more in informatics and getting closer to the customer, and they really embedded themselves into having insurance payers and employing technology and improving their product and rolling it out."

According to Jenneke, the worst economic hurdles for growth stocks would be over this year.

"We see growth in inflation peaking in 2021," he said.

"What that means is that when we get into the later part of 2021 and into 2022, we should expect the market leadership is probably going to start to change."

At the time of writing, the Resmed share price is trading at $29.87, up 5.29%.

Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to almost 30%

Analysts are tipping these shares to deliver big returns over the next 12 months.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Guess which beaten down ASX share is rocketing 11% today

Why are investors buying this beaten down stock? Let's find out.

Read more »

Broker working with share prices on computers.
Broker Notes

These 3 ASX All Ords stocks just got sizeable broker upgrades

Top brokers expect strong performance from these ASX All Ords stocks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Morgans says these ASX 200 stocks can rise 30%

Big returns could be on the cards for buyers of these shares.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »